Ruxolitinib 5 MG

DRUG2 trials

Sponsors

Lomonosov Moscow State University Medical Research and Educational Center, University of Pennsylvania

Conditions

COVID 19Refractory AMLRelapsed AML

Phase 1

CART123 + Ruxolitinib in Relapsed/Refractory AML

Active, not recruitingNCT06768476

University of PennsylvaniaRefractory AML, Relapsed AML

Start: 2025-02-28End: 2045-03-01Target: 12Updated: 2026-01-16

Phase 2

COLchicine Versus Ruxolitinib and Secukinumab in Open-label Prospective Randomized Trial in Patients With COVID-19

CompletedNCT04403243

Lomonosov Moscow State University Medical Research and Educational CenterCOVID 19

Start: 2020-05-08End: 2020-08-23Updated: 2022-11-25